Advaita receives $125,000 Michigan Emerging Systems Fund award Advaita Company, a startup company based on technology developed at Wayne Condition University by Sorin Draghici, Ph medicine for early ejection .D., professor of pc science in the faculty of Engineering, received the final installment of a $125,000 award from the Michigan Emerging Technologies Fund program. This comes on the heels of a $2.2 million Phase II SMALL COMPANY Technology Transfer grant, ‘Pathway-Guide: A Novel Device for the Analysis of Signaling and Metabolic Pathways,’ awarded to Advaita in 2011 by the National Institute of General Medical Sciences of the National Institutes of Health. Advaita Corporation has developed a bioinformatics software option called Pathway-Guide that provides the innovative gene pathway evaluation technology to date, predicated on intellectual property developed at Wayne Condition University.
In cancers, TAMs are versatile and may either support or inhibit cancer tumor progression. In PTCs, BRAF activation in the thyroid can be accompanied by increased levels of colony stimulating factor 1, which stimulates the recruitment of TAMs to the thyroid. Once in the thyroid, TAMs accumulate alongside cancer-linked myofibroblasts to form a dense level within and around the thyroid. The experts used genetic techniques to destroy the TAMs in PTCs. The result was a significant reduction in PTC size, total tumor cell quantity and a more well-differentiated, less advanced PTC. The authors demonstrated a functional hyperlink between TAMs also, the recruitment of PTC and CAMs initiation.